The United States market remained flat over the last week, yet it has experienced a significant 28% rise over the past 12 months with earnings projected to grow by 16% annually. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those who know the business best.

Top 10 Growth Companies With High Insider Ownership In The United States

Name	Insider Ownership	Earnings Growth
Uxin (UXIN)	35.7%	74.1%
Upstart Holdings (UPST)	12.8%	53.8%
Precigen (PGEN)	11.9%	68.4%
Karman Holdings (KRMN)	17%	53.2%
Enovix (ENVX)	12.4%	41.1%
Clene (CLNN)	12%	62.2%
Caledonia Mining (CMCL)	14.1%	29.6%
Better Home & Finance Holding (BETR)	19.3%	100.6%
Astera Labs (ALAB)	10.8%	27.8%
AppLovin (APP)	27.4%	22.1%

Let's take a closer look at a couple of our picks from the screened companies.

Enovix (ENVX)

Simply Wall St Growth Rating: ★★★★★★

Overview: Enovix Corporation designs, develops, and manufactures lithium-ion battery cells both in the United States and internationally, with a market cap of $1.44 billion.

Operations: The company's revenue segment consists of $31.82 million from its Batteries / Battery Systems division.

Insider Ownership: 12.4%

Enovix is trading significantly below its estimated fair value, with strong growth prospects. Its revenue is expected to grow at 36.3% per year, surpassing the US market average. The company is forecasted to become profitable within three years, with earnings growing at 41.13% annually. Recent financial results show improved sales and reduced net losses compared to the previous year, although insider trading activity remains unchanged recently. Enovix has completed a share buyback program and filed a shelf registration for $65 million in common stock offerings related to an ESOP initiative.

ImmunityBio (IBRX)

Simply Wall St Growth Rating: ★★★★★☆

Overview: ImmunityBio, Inc. is a biotechnology company dedicated to developing and commercializing next-generation immunotherapies aimed at activating the immune system for long-lasting protection against cancer and infectious diseases, with a market cap of approximately $7.34 billion.

Operations: The company's revenue segment is primarily focused on developing next-generation therapies, generating $113.29 million.

Insider Ownership: 28.6%

ImmunityBio is experiencing robust growth, with revenue forecasted to increase by 52% annually, outpacing the US market's average. Despite recent shareholder dilution and highly volatile share prices, the company is expected to achieve profitability within three years. Recent product approvals in Saudi Arabia and other regions for ANKTIVA highlight its expanding global presence. However, legal challenges and regulatory scrutiny over promotional practices present ongoing risks. The company's cash runway remains limited to less than a year, necessitating careful financial management.

Wealthfront (WLTH)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Wealthfront Corporation is a privately owned investment manager with a market cap of $1.62 billion.

Operations: The company generates revenue primarily through its asset management segment, which accounts for $365 million.

Insider Ownership: 14.2%

Wealthfront Corporation's recent inclusion in multiple Russell indices underscores its recognition as a growth entity, though its financials present a mixed picture. The company's revenue rose to US$96.14 million in Q4 2026, yet it recorded a net loss of US$133.66 million compared to the previous year's profit. Despite this, Wealthfront is projected to achieve profitability within three years and has initiated a US$100 million share buyback program, signaling confidence in future prospects amidst high insider ownership levels.

Next Steps

• Take a closer look at our Fast Growing US Companies With High Insider Ownership list of 193 companies by clicking here.
• Searching for a Fresh Perspective? The end of cancer? These 31 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.